Business Wire

Transphorm’s SuperGaN Gen V FET Delivers World’s Lowest Packaged On-resistance, Targeting Electric Vehicle Applications

2.12.2020 14:00:00 EET | Business Wire | Press release

Share

Transphorm Inc. (OTCQB: TGAN)—a pioneer and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the sampling of its first Gen V device under its proprietary SuperGaNTM brand. The TP65H015G5WS, Transphorm’s new Gen V device, targets the Electric Vehicle (EV) market and provides industry-leading performance enhancements, ease of designability, and optimized cost structure that is inherent to the SuperGaN device family. Notably, the Company’s Gen V GaN solution offers the world’s lowest packaged on-resistance and delivers a 25% lower power loss over Silicon Carbide (SiC) in a standard TO-247-3 package, strengthening the potential of GaN in the EV power conversion market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005276/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lowest Rds(on) SuperGaN™ FET in a TO-247 package from Transphorm poised for growth in EV market. (Graphic: Business Wire)

In March 2020, Marelli, one of the world's leading global independent suppliers to the automotive sector, announced a strategic partnership with Transphorm to collaborate on new GaN-based automotive/EV power conversion solutions including On-board Chargers (OBCs), DC-DC Converters and Powertrain Inverters for electric and hybrid vehicles. To date, Marelli has made a $4 million equity investment in Transphorm and has committed to an additional $1 million equity investment in Q1 2021.

Dr. Joachim Fetzer, CEO, Electric Powertrain Marelli, commented, “Transphorm’s demonstration of achieving 10 kilowatts of power from a discrete packaged GaN device in a bridge configuration is further validation of the exciting promise of GaN for electric vehicle converters and inverters. As part of our previously announced partnership, we will continue to evaluate Transphorm’s industry-leading GaN devices and work together in support of a multi-year EV systems product roadmap.”

“We continue to innovate Transphorm’s SuperGaN FET technology, now offering the world’s lowest on-resistance in a standard TO-247-3 package in the market, targeted for electric vehicles and other higher power conversion applications. This allows customers to drive into double digit kilowatts with a single device, continuing to demonstrate GaN’s ability to provide higher performance, lower system cost and higher power density,” said Primit Parikh, COO and Co-founder, Transphorm. “Our Gen V GaN platform is creating new design opportunities for power levels that previously required paralleling, while still offering the greater than 99% efficiency.”

Transphorm’s SuperGaN Technology Outperforms Silicon Carbide

The SuperGaN Gen V platform incorporates all the learnings from its Gen IV predecessor, patented reduced packaging inductance technology, ease of designability and drivability (Vth of 4 V for noise immunity), and gate robustness of +/- 20 Vmax along with a simplified and reduced assembly structure. In a recent article published in EEWorld, “Pushing the Boundaries of High Voltage GaN Power Conversion,” the company’s TP65H015G5WS was compared to a similar on-resistance leading-edge SiC MOSFET in a standard TO-247-3 package. The devices were both operated up to 12 kW at 70 kHz in a half bridge synchronous boost converter, resulting in Transphorm’s GaN device demonstrating up to 25% lower losses.

Transphorm has begun sampling the SuperGaN Gen V FET, a 15 mΩ 650 V device, which is unavailable with today’s single chip e-mode GaN technology due to its gate sensitivity. Matching the lowest R available from typical SiC MOSFETs in a discrete package, the solution is capable of driving more than 10 kW depending on the target application, such as EV OBCs and powertrain inverters, power supplies for rack powered data center servers, uninterruptible industrial power applications, and renewable photovoltaic inverters. The TP65H015G5WS will also be available for die level module solutions that enable further paralleling for even higher power. The Company anticipates its Gen V FET device to receive JEDEC qualification in mid-2021 with AEC-Q101 qualification expected thereafter.

About Marelli

MARELLI is one of the world’s leading global independent suppliers to the automotive sector. With a strong and established track record in innovation and manufacturing excellence, our mission is to transform the future of mobility through working with customers and partners to create a safer, greener and better-connected world. With around 60,000 employees worldwide, the MARELLI footprint includes 170 facilities and R&D centers across Asia, the Americas, Europe, and Africa, generating revenues of 13.4 Billion Euro (JPY1,541billion) in 2019.

About Transphorm

Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company’s vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm’s innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa.

The SuperGaN mark is a registered trademark of Transphorm, Inc. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Transphorm Contact:
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

Marelli Contacts:
Maurizio Scrignari
maurizio.scrignari@marelli.com
Daniela Di Pietrantonio
daniela.dipietrantonio@marelli.com
Tel.: +39 02 972.27.903
Communication Department, Japan
pr@marelli.com
Tel.: +81-48-660-2161

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 17:05:00 EEST | Press release

Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive

Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 16:00:00 EEST | Press release

Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma has built one of the industry’s deepest operational quality platforms, combining best-practice workflows with software designed to work natively on factory floors worldwide. This unique operational foundation has ge

Tecnotree allekirjoitti 17,5 miljoonan Yhdysvaltain dollarin monivuotisen sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella13.8.2026 15:04:00 EEST | Tiedote

Tecnotree, joka on maailmanlaajuinen 5G- ja tekoälynatiivien digitaalisten BSS-ratkaisujen sekä teleoperaattoreille suunnattujen digitaalisen transformaation ratkaisujen toimittaja, ilmoitti eilen allekirjoittaneensa uuden monivuotisen ja usean alueen kattavan sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella. Sopimus kuvastaa Tecnotreen jatkuvaa painotusta pitkäaikaisten asiakassuhteiden laajentamiseen yhtiön 5G- ja tekoälynatiivien digitaalisten alustojen ja palvelujen avulla, jotka auttavat teleoperaattoreita uudistamaan liiketoimintaansa, nopeuttamaan palveluinnovaatioita ja parantamaan asiakaskokemusta. Tecnotree jatkaa operaattoreiden muuttuvien digitaalisen transformaation painopisteiden tukemista maailmanlaajuisesti. ”Amerikan alue on Tecnotreelle edelleen tärkeä markkina-alue, jolla yhtiö jatkaa teleoperaattoreiden tukemista ratkaisuilla, jotka yksinkertaistavat toimintaa, mahdollistavat liiketoiminnan ketteryyden ja luovat kestävää arvoa seuraavan sukupolv

Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 15:00:00 EEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterprises, researchers, startups and public sector organizations seeking access to advanced AI infrastructure. This capacity is part of Nebius’ broader UK expansion and commitment to scale domestic AI compute capacity. In

SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 13:30:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year. Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year. Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points year-over-year. Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year. The Company believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye